MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
1.440
-0.030
-2.04%
Opening 11:30 06/25 EDT
OPEN
1.470
PREV CLOSE
1.470
HIGH
1.515
LOW
1.440
VOLUME
27.91K
TURNOVER
--
52 WEEK HIGH
12.64
52 WEEK LOW
1.326
MARKET CAP
6.19M
P/E (TTM)
-0.3229
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACXP last week (0615-0619)?
Weekly Report · 3d ago
Acurx says lead antibiotic ibezapolstat is ready to enter pivotal Phase 3 trials for C. difficile infection
PUBT · 06/16 12:03
ACURX PHARMACEUTICALS ANNOUNCES PRESENTATION OF RESULTS FROM LEIDEN UNIVERSITY MEDICAL CENTER PUBLIC-PRIVATE PARTNERSHIP FOR ITS DNA POL IIIC INHIBITORS AT THE LEIDEN EARLY DRUG DISCOVERY & DEVELOPMENT (LED3) SCIENTIFIC CONFERENCE
Reuters · 06/16 12:00
Weekly Report: what happened at ACXP last week (0608-0612)?
Weekly Report · 06/15 10:31
Weekly Report: what happened at ACXP last week (0601-0605)?
Weekly Report · 06/08 10:26
Weekly Report: what happened at ACXP last week (0525-0529)?
Weekly Report · 06/01 10:31
Weekly Report: what happened at ACXP last week (0518-0522)?
Weekly Report · 05/25 10:35
Weekly Report: what happened at ACXP last week (0511-0515)?
Weekly Report · 05/18 10:34
More
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Webull offers Acurx Pharmaceuticals Inc stock information, including NASDAQ: ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.